Pharmaceuticals

Research Reports in Pharmaceuticals

Diabetic Neuropathy – Drug Pipeline Landscape, 2022
November, 2022

Diabetic neuropathy is a type of nerve damage that can occur in people with diabetes. High blood sugar levels can damage the nerves over time. This type of damage is called neuropathy. Diabetic neuropathy can affect different parts of the body, including the feet, legs, hands, and arms. It can also affect the digestive system, urinary system, blood vessels, and heart. Diabetic neuropathy is a serious complication of diabetes. It can lead to problems with the feet, legs, and hands. It can also lead to problems with the digestive system, urinary system, blood vessels, and heart.

Diabetic neuropathy can cause due to the high blood glucose levels, also called blood sugar, and high levels of fats, such as triglycerides, in the blood from diabetes can damage nerves. High blood glucose levels can also damage the small blood vessels that nourish nerves with oxygen and nutrients.

Symptoms of diabetic neuropathy includes loss of sensation in their feet, burning or shooting pain in their lower legs, muscle weakness or wasting, bladder problems such as incomplete bladder emptying, vision trouble such as double vision.

Doctors most often diagnose diabetic neuropathy by asking about symptoms and physical examination. The tests include filament test, sensory test, nerve conduction test, autonomic test, and electromyography.

The most common investigative treatments include anti-seizure drugs, antidepressants to ease pain. Symptoms can be eased through lifestyle changes and home remedies like physically active, follow diabetes meal plan, quit smoking, and limit alcoholic drinks to no more than one drink per day.

Report Highlights

Global Insight Service’s, Diabetic Neuropathy – Drug Pipeline Landscape, 2022 report provides an overview of the Diabetic Neuropathy pipeline drugs. This report covers detailed insights on Diabetic Neuropathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Neuropathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Acute Myeloid Leukemia (AML) – Drug Pipeline Landscape, 2022
November, 2022

Leukemia is a malignant disease of the blood cells. The four main types of leukemia are acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). AML is the most common type of leukemia in adults, accounting for about 80% of all cases.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) is a type of blood cancer in which the bone marrow produces a large number of abnormal blood cells which is also called as Acute Myeloid Leukemia, Acute Granulocytic Leukemia and Acute Nonlymphocytic Leukemia.

The most common causes of Acute Myelocytic Leukemia are mutations in the DNA, smoking, previous chemotherapy treatment, exposure to radiation, hazardous chemical exposure, age, other genetic or blood disorders.

The most common symptoms of Acute Myelocytic Leukemia include fever, fatigue, paleness or loss of normal skin colour, unusual bleeding/ bruises, frequent infections, headache, weight loss, shortness of breath etc.

Acute Myelocytic Leukemia can be diagnosed by the doctors by a physical exam to look for signs of bleeding, bruising, or infection. Diagnostic tests include Blood tests, Imaging tests, Bone marrow tests, Spinal tap, Genetic tests etc.

The most common treatments for Acute Myelocytic Leukemia are Chemotherapy, Radiotherapy, Stem cell transplantation, Targeted therapy with either or combinations as Remission induction therapy and Consolidation therapy.

The prognosis for AML varies depending on the age of the patient and the subtype of the disease. In general, the outlook is better for younger patients and those with certain subtypes of AML. With treatment, many people are able to achieve remission, but the disease can recur.

Report Highlights

Global Insight Service’s, Acute Myeloid Leukemia (AML) – Drug Pipeline Landscape, 2022 report provides an overview of the Acute Myeloid Leukemia (AML) pipeline drugs. This report covers detailed insights on Acute Myeloid Leukemia (AML) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Acute Myeloid Leukemia (AML) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Helicobacter Pylori Testing Market
November, 2022

The global Helicobacter Pylori Testing Market was valued at USD 436.0 Million in 2021 and it is anticipated to grow up to USD 915.4 Million by 2031, at a CAGR of 7.7% during the forecast period.

Helicobacter pylori testing is a way to determine if a person has an infection with the bacteria Helicobacter pylori. This bacteria is known to cause stomach ulcers, and testing can help to diagnose an infection and determine the best course of treatment. There are a few different ways to test for H. pylori, including a stool sample, a breath test, or a biopsy.

Global Helicobacter Pylori Testing Market Scope and Report Structure
Report Attribute Details
Market Size in 2021$436.0 mn
Market Size in 2031$915.4 mn
Growth Rate (2021-31)7.7 %
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredTest Type, Method, End-user, and Region
Key CompaniesAbbott Laboratories, Avanos Corporate, Biohit Oyj, Bio-Rad Laboratories, Inc., Cardinal Health, Exalenz Bioscience Ltd., Gulf Coast Scientific, Medline Industries, Inc. , Thermo Fisher Scientific Inc. and QIAGEN.
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The most important driver of the H. pylori testing market is the high prevalence of H. pylori infection. It is estimated that H. pylori infects more than half of the world’s population. The prevalence is highest in developing countries and lowest in developed countries. The second important driver of the H. pylori testing market is the increasing awareness of the link between H. pylori infection and gastric cancer. Gastric cancer is the fourth most common cancer in the world and the second leading cause of cancer death. H. pylori infection is a major risk factor for gastric cancer. The third important driver of the H. pylori testing market is the increasing incidence of ulcers. Ulcers are a common condition and their incidence is increasing due to the increasing prevalence of H. pylori infection. The fourth important driver of the H. pylori testing market is the increasing demand for rapid and accurate testing methods. The currently available methods for H. pylori testing are culture, histology, urea breath test, and stool antigen test. However, these methods are time-consuming and expensive. The fifth important driver of the H. pylori testing market is the development of new and improved testing methods. Newer methods, such as PCR and ELISA, are more rapid and accurate than the older methods.

Market Restraints and Challenges

Helicobacter pylori infection is typically diagnosed through an invasive procedure, which entails biopsy and endoscopy, and requires advanced operational skills for precisely diagnosing and identifying the appropriate treatment method. However, the lack of trained professionals in nations with limited healthcare resources may affect the disease testing rates, dampening the market progress. Many low and middle-income economies lack the hospital and medical training infrastructure needed to highly skilled physicians. Helicobacter pylori treatment also poses other challenges for physicians as no first-line therapy can treat the infection for all patients.

Global Helicobacter Pylori Testing Market Segmental Overview

The report analyses the global Helicobacter Pylori Testing Market based on test type, method, end-user, and region.

Global Helicobacter Pylori Testing Market by Test Type

Based on test type, the market is segregated as Invasive, and Non-invasive. Amongst them, invasive helicobacter test segment is poised to register a significant CAGR from 2023 to 2031, driven by the efficacy and cost-effectiveness of rapid urease tests. The demand for invasive testing method is also high among patients do not correspond well to antibiotic therapy, have symptoms of severe gastric problems, and further require gastric endoscopy.

Global Helicobacter Pylori Testing Market by Method

On the basis of the method, the helicobacter pylori testing market is categorized into laboratory-based tests and point-of-care (POC) tests. The POC tests segment accounted for a significant business share in 2022, due to its non-invasive nature and its ability to deliver fast results. This is also attributed to collaborative research initiatives by leading industry giants and increasing R&D spending, which is further encouraging technological advancements as well as new product launches.

Global Helicobacter Pylori Testing Market by End-user

With regards to end-user, the Helicobacter Pylori Testing Market is divided into Hospital & Clinics, Diagnostic labs, and others. Hospital & Clinics generated considerable revenue in 2021 and is expected to grow at a highest CAGR over the analysis period. This is owing to the rising patient preference for clinics due to affordability and quality care. This is driven by the high-quality treatment and quick assistance offered by clinics, which provides the desired treatment results at a reasonable cost. In addition, the high-end services offered by clinics through effective disease management strategies are further set to spur segment expansion.

Geographical Analysis of Global Helicobacter Pylori Testing Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America Helicobacter Pylori Testing Market revenue is poised to grow significant CAGR during the forthcoming years. This can be attributed to the presence of industry leaders, as well as an emphasis on continual technological developments and new product releases, has contributed to the regional market’s growth. Revenue growth is slated to be fueled by the rising occurrences of infectious ailments and increasing aging population in the region. Poor healthcare infrastructure and low awareness about good sanitary practices across developing APAC economies is further projected to fuel the demand for helicobacter pylori tests.

Major Players in the Global Helicobacter Pylori Testing Market

The key players in the Helicobacter Pylori Testing Market Abbott LaboratoriesAvanos CorporateBiohit OyjBio-Rad Laboratories, Inc.Cardinal HealthExalenz Bioscience Ltd.Gulf Coast ScientificMedline Industries, Inc. Thermo Fisher Scientific Inc. and QIAGEN. among others.

COVID-19 Impact

In the initial months of 2020, COVID-19 made a severe negative impact on the h. pylori testing industry. Many h. pylori patients avoided hospital visits on account of the rapidly increasing COVID-19 cases and mortality rates, which overwhelmed healthcare facilities and spread infection fears among the global population. Additionally, the infection risks associated with invasive helicobacter pylori testing at point-of-care treatment units also led to disruption in the sector. Since the route of virus transmission is nasal or oral, the non-invasive tests such as the urea breath tests (UBT) were also impacted as they held a high possibility of COVID-19 transmission. Now, as successful vaccination drives turn COVID-19 into an afterthought, the market is expected to bounce back in a notable manner.

Recent Developments
  • In June 2022, Phathom Pharmaceuticals announced that FDA approved Voquenza (vonoprazan fumarate), in combination with anti-biotics, for H.pylori infection.
  • In September 2021, Phathom Pharmaceuticals Submited two NDAs to U.S. FDA for Vonoprazan-based treatment regimens for the treatment of H. pylori infection.
  • In July 2021, Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc.
  • In March 2020, RedHill Biopharma Ltd., announced the U.S. commercial launch of Talicia® 1 delayed-release capsules 10 mg2/250 mg/12.5 mg for the treatment of Helicobacter pylori (H. pylori) infection in adults. RedHills expanded U.S. sales force will promote Talicia® nationwide to approximately 25,000 gastroenterologists, primary care physicians and other healthcare providers.
Frequently Asked Questions

Q1. How big is the Helicobacter Pylori Testing Market ?

Ans. The global Helicobacter Pylori Testing Market was valued at USD 436.0 Million in 2021 and it is anticipated to grow up to USD 915.4 Million by 2031, at a CAGR of 7.7% during the forecast period.

Q2. What is the Helicobacter Pylori Testing Market growth rate?

Ans. The growth rate of the Helicobacter Pylori Testing Market is 17.1%.

Q3. Which region holds a major market share for the market?

Ans. North America holds a major market share of the Helicobacter Pylori Testing Market in 2021.

Q4. Which segment accounted for the largest Helicobacter Pylori Testing Market share?

Ans. By end user, the hospital& clinics segment accounted for the largest Helicobacter Pylori Testing Market share.

Q5. Who are the key players in the digital diabetes management market?

Ans. The global Helicobacter Pylori Testing Market report includes players such as  Abbott LaboratoriesAvanos CorporateBiohit OyjBio-Rad Laboratories, Inc.Cardinal HealthExalenz Bioscience Ltd.Gulf Coast ScientificMedline Industries, Inc. Thermo Fisher Scientific Inc. and QIAGEN, among others.

Q6. What are the factors driving the Helicobacter Pylori Testing Market growth?

Ans. The major factors driving the growth of the market are growing prevalence of H, pylori across the globe.

Q7. What are the key growth strategies of Helicobacter Pylori Testing Market players?

Ans. The key growth strategies of Helicobacter Pylori Testing Market players are product launch and product approval.

Q8. Which region will provide more business opportunities for the Helicobacter Pylori Testing Market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the Helicobacter Pylori Testing Market during the forecast period.

Read More
Single User License

Diabetic Gastroparesis – Drug Pipeline Landscape, 2022
November, 2022

Diabetic Gastroparesis is a serious complication of diabetes resulting in delayed gastric emptying with associated upper gastrointestinal (GI) symptoms in the absence of any mechanical obstruction. Gastroparesis is a digestive disorder with a high incidence among people with long-standing diabetes.

Gastroparesis can cause due to the damage of vagus nerve. Certain medications, such as opioid pain relievers, some antidepressants, and high blood pressure and allergy medications, can lead to slow gastric emptying and cause similar symptoms.

Symptoms of diabetic gastroparesis includes nausea, vomiting and abdominal pain. It can also cause problems with blood sugar levels and nutrition, feeling of fullness after eating just a few bites, vomiting undigested food eaten a few hours earlier, acid reflux, changes in blood sugar levels, lack of appetite, weight loss and malnutrition.

Doctors most often diagnose diabetic gastroparesis by using the tests such as scintigraphy, breath tests, upper gastrointestinal (GI) endoscopy, wireless motility capsule, barium X-ray, gastric manometry, radioisotope gastric-emptying scan.

The most common investigative treatments include metoclopramide (Reglan) and erythromycin. Surgery in some cases may improve outcomes. Symptoms can be eased through lifestyle changes and home remedies like eating smaller meals more frequently, avoid fibrous fruits and vegetables, drink about 34 to 51 ounces (1 to 1.5 liters) of water a day.

Report Highlights

Global Insight Service’s, Diabetic Gastroparesis – Drug Pipeline Landscape, 2022 report provides an overview of the Diabetic Gastroparesis pipeline drugs. This report covers detailed insights on Diabetic Gastroparesis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Gastroparesis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Hyperparathyroidism – Drug Pipeline Landscape, 2022
November, 2022

Hyperparathyroidism is a disease characterized by excessive secretion of parathyroid hormone, an 84–amino acid polypeptide hormone. The secretion of parathyroid hormone is regulated directly by the plasma concentration of ionized calcium. Primary hyperparathyroidism is a common endocrine disorder caused by overactivation of parathyroid glands resulting in excessive release of parathyroid hormone.

Secondary hyperparathyroidism mainly occurs when the calcium proportion in the body is dropped or reduced due to certain core ailments. Prolonged kidney illness also results in lowering Vitamin D and calcium, which results in secondary hyperparathyroidism.

The most common cause of hyperparathyroidism is having a long history of calcium and vitamin deficiencies, chronic kidney failure that results in low vitamin D and calcium levels.

Symptoms of hyperparathyroidism includes exhaustion, weakness of muscle and joints, body pains, loss of appetite, constipated bowels, motion sickness, fatigue, unable to concentrate and confusion, depression, nausea and vomiting, kidney stones etc.

Doctors most often diagnose hyperparathyroidism by general medical examination of the skin, eye, throat, pulse rate. A blood test is performed to detect the calcium level and hormone level of thyroid-stimulating Hormone including T3 and T4. CT, MRI, and Ultrasound Scans are conducted to detect the presence of a tumour or the swelling of the gland.

The most common investigative treatments include are few antithyroid and radioactive iodine medication is taken to control the overproduction of parathyroid hormone. In extreme cases, surgery is performed to remove the thyroid gland. Symptoms can be eased through lifestyle changes and home remedies like Regular walk and exercise for stronger and healthy bones., Intake of more water and fresh fruit juice to avoid dehydration., Having a balanced diet including Vitamin D-rich food and calcium supplements.

Report Highlights

Global Insight Service’s, Hyperparathyroidism – Drug Pipeline Landscape, 2022 report provides an overview of the Hyperparathyroidism pipeline drugs. This report covers detailed insights on Hyperparathyroidism drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Hyperparathyroidism pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Male Hypogonadism – Drug Pipeline Landscape, 2022
November, 2022

Male Hypogonadism is characterized by a decrease in testosterone level or lack of spermatozoa production or both. When a disorder related to the testes it is called primary hypogonadism or if it related to the hypothalamic-pituitary axis it is called secondary hypogonadism.

Causes of hypogonadism include HIV or AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles, and untreated sleep apnea.

Symptoms of hypogonadism include fatigue, hot flashes, infertility, decrease in muscle mass, and loss of bone mass

Doctor diagnose hypogonadism based on a physical exam, a review of symptoms, and the results of multiple blood tests which will detect low testosterone levels.

Male hypogonadism is usually treated with testosterone replacement to return testosterone levels to normal and natural therapies which will increase testosterone production including diet and exercise, weight loss, improved sleep.

Report Highlights

Global Insight Service’s, Male Hypogonadism – Drug Pipeline Landscape, 2022 report provides an overview of the Male Hypogonadism pipeline drugs. This report covers detailed insights on Male Hypogonadism drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Male Hypogonadism pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Migraine – Drug Pipeline Landscape, 2022
November, 2022

Migraine is a neurological disorder that is associated with recurrent headaches. The headache is characterized by affecting one side of the head, pulsating, moderate to severe in intensity which last for few hours to three days.

The underlying cause of migraine is unknown. It is believed that, migraine may be due to a mixture of environmental triggers and genetical factors. Change in hormonal levels during puberty may also affect the cause of migraine. Triggering factors include fatigue, certain foods, alcohol, and whether. Psychological stress quoted to be a risk factor.

The symptoms of migraine is presented one or two days before the attack, which is presented as constipation, mood changes, fatigue, fluid retention, frequent yawning, and increased urination. Few people experience migraine aura, including visual phenomena, vision loss, pins and needles sensation in arm and legs, weakness or numbness in the face and difficulty speaking. Symptoms during migraine attack includes pain on one of the head, pain throbbing or pulsing, sensitivity to light, sound, smell and touch, and also experience nausea and vomiting.

The migraine diagnosis is based on medical history, symptoms, physical and neurological examination, Neuroimaging tests are used to find other causes of headaches which includes MRI and CT scans.

The treatment plan of migraines includes the combination of lifestyle adjustments, OTC pain or migraine medications like NSAIDs, triptans, dihydroergotamine, CGRP antagonists, opioid medications, anti-nausea drugs, alternative care includes meditation, acupressure or acupuncture.

Report Highlights

Global Insight Service’s, Migraine – Drug Pipeline Landscape, 2022 report provides an overview of the Migraine pipeline drugs. This report covers detailed insights on Migraine drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Migraine pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Interstitial Cystitis – Drug Pipeline Landscape, 2022
November, 2022

Interstitial cystitis also called painful bladder syndrome, is a chronic bladder problem usually related to bladder pressure and pain, with irregular pain in either the lower abdomen, pelvis or lower back. There are two types of interstitial cystitis: non-ulcerative interstitial cystitis and Ulcerative interstitial cystitis.

Causes of interstitial cystitis include age, chronic pain disorders, such as irritable bowel syndrome or fibromyalgia, and some of the factors contributing to interstitial cystitis are a defect of the epithelium layer of the bladder and leaking epithelium allows toxic agents in urine to irritate the bladder wall.

Interstitial cystitis is prone to affect women more than men. Common symptoms of interstitial cystitis include bladder pain and pressure, frequent urination, pain in the vagina or vulva in the case of women, and pain in the scrotum or testicles in the case of men.

Interstitial cystitis is diagnosed by Urine analysis and cystoscopy to look inside the urethra and bladder.

Interstitial cystitis is treated by non-steroidal anti-inflammatory drugs, antidepressants, and antihistamines.

Report Highlights

Global Insight Service’s, Interstitial Cystitis – Drug Pipeline Landscape, 2022 report provides an overview of the Interstitial Cystitis pipeline drugs. This report covers detailed insights on Interstitial Cystitis drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Interstitial Cystitis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Psoriasis – Drug Pipeline Landscape, 2022
November, 2022

Psoriasis also known as psoriasis vulgaris, which is a chronic, proliferative and inflammatory autoimmune disease characterized by raised areas of abnormal skin as itchy, scaly and patchy. There are five main types of psoriasis – plaque, guttate, inverse, pustular and erythrodermic.

The cause of psoriasis is still unknown. A rare mutation in the gene encoding CARD14 along with environmental trigger causes plaque psoriasis. Chronic infections, stress, changes in the season and climate may worsen the condition. Psoriasis can occur by the microbes including S. aureus, C. albicans. Etc., At some times psoriasis can also occurs due to medicaments like beta blockers, antimalarials, TNF inhibitors, etc.,

Common signs and symptoms are inflamed skin covered with silvery white scaly skin. Bumps filled with non-infectious pus is formed. In severe cases, the plaques will grow. Bleeding occurs from the itchy and painful skin. Discoloration and detachment of fingernails and toenails from the nail bed occurs.

Psoriasis is diagnosed based on the skin appearance. No special blood tests or diagnostic procedures are required. Skin biopsy or scraping is performed.

Treatment for psoriasis is aimed to stop skin cells from growing quickly and to remove scales. Emollients are used to keep skin moisturized. Corticosteroids, synthetic vitamin D, retinoids and pimecrolimus cream and tacrolimus ointment are preferred. Phototherapy is also recommended which suppresses immune activity and reduce irritation.

Report Highlights

Global Insight Service’s, Psoriasis – Drug Pipeline Landscape, 2022 report provides an overview of the Psoriasis pipeline drugs. This report covers detailed insights on Psoriasis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Psoriasis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Chronic Urticaria or Hives – Drug Pipeline Landscape, 2022
November, 2022

Urticaria is an itchy rash that appears on the skin. It may appear on one part of the body or be spread across large areas. Chronic urticaria is a mast cell-mediated condition characterized by the recurrent occurrence of urticaria and/or angioedema.

The welts that come with hives are caused by the release of immune system chemicals, such as histamine, into the bloodstream. The skin reaction may be triggered by heat or cold, sunlight, vibration, pressure on the skin, medical conditions, such as thyroid disease, infection, allergy, and cancer.

Symptoms of chronic hives includes batches of welts (wheals) that can arise anywhere on the body, welts that might be red, purple, or skin colored. Welts that vary in size, change shape, and appear and fade repeatedly, Itchiness (pruritus), which can be intense, painful swelling (angioedema) around the eyes, cheeks, or lips.

Doctors most often diagnose chronic urticaria by examining the rash. The tests include complete blood count, erythrocyte sedimentation rate and C reactive protein are important investigations for diagnosis of infections in urticaria.

The most common investigative treatments include antihistamines. These drugs ease itching, swelling and other allergy symptoms. Second-generation H1-antihistamines (e.g., cetirizine, loratadine, fexofenadine), taken regularly, are the first-line pharmacological treatment. Omalizumab given as a subcutaneous injection is a second-line adjunct therapy for CSU that is unresponsive to H1-antihistamines.

Symptoms can be eased through lifestyle changes and home remedies like comfortably cool shower or bath, wear loose, smooth-textured cotton clothing and protect your skin from the sun.

Report Highlights

Global Insight Service’s, Chronic Urticaria or Hives – Drug Pipeline Landscape, 2022 report provides an overview of the Chronic Urticaria or Hives pipeline drugs. This report covers detailed insights on Chronic Urticaria or Hives drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Chronic Urticaria or Hives pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Venous Thromboembolism – Drug Pipeline Landscape, 2022
November, 2022

Venous thrombosis occurs due to the blockage of the veins caused by a thrombus (blood clot). A common form of venous thrombosis is deep vein thrombosis (DVT), this occurs when blood clots in the deep veins. If a blood clot breaks off (embolizes) and flows to the lungs to lodge, then it becomes a pulmonary embolism (PE). The conditions including DVT only, DVT with PE, and PE only altogether referred as “Venous Thromboembolism”.

Venous thromboembolism is caused by a combination of venous stasis and hypercoagulability, and to a lesser extent endothelial damage and activation also plays a crucial role. The most common causes are injury and infections. In some cases, it might be due to medical intervention including surgery, chemotherapy, inserting IV or catheter.

Venous thromboembolism can be diagnosed by the initial screening through the signs and symptoms of the condition. DVT are diagnosed through blood tests, vascular ultrasound, MR venography and contrast venography. PE can be diagnosed through pulse oximetry, chest X-ray, CT pulmonary angiography and pulmonary angiogram.

Venous Thromboembolism is diagnosed through CT pulmonary angiography – also called CT pulmonary embolism which creates 3dimensional images that can detect abnormalities such as pulmonary embolism within the arteries in the lungs.

Venous thromboembolism treatment goals are to prevent clot from getting bigger, from breaking loose and traveling to the lungs and chances of another DVT. Medication includes anticoagulants, thrombolytics, inferior vena cava filters and superficial venous thrombosis. In rare cases, a surgical procedure is included to remove the clot. Thrombectomy – removal of clots in DVT patients and embolectomy – removal of blockages caused by the clots in in the lungs in PE patients.

Report Highlights

Global Insight Service’s, Venous Thromboembolism – Drug Pipeline Landscape, 2022 report provides an overview of the Venous Thromboembolism pipeline drugs. This report covers detailed insights on Venous Thromboembolism drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Venous Thromboembolism pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Polycystic Kidney Disease (PKD) – Drug Pipeline Landscape, 2022
November, 2022

Polycystic Kidney Disease (PKD or PCKD) also known as polycystic kidney syndrome, is a genetic disorder. This causes the flued filled cysts within the kidney. This is a form of chronic kidney disease which results in the reduction of kidney function, which may lead to kidney failure. PKD is mainly of two types: autosomal dominant PKD (ADPKD) and autosomal recessive PKD (ARPKD).

PKD is caused due to the abnormal genes which produces abnormal protein. This abnormal protein has an adverse effect on tubule development.

Signs and symptoms include high blood pressure, abdominal pain, back pain, blood in urine, excessive urination and headaches.

PKD can be diagnosed using imaging test such as CT scan of abdomen, MRI and ultrasound. Genetic testing is also done in some situations. A physical examination is also preferred including liver, heart murmurs and elevated blood pressure.

PKD treatment focuses on the slowing of the disease progression through maintaining normal blood pressure, low-salt intake, weight control, dietary protein restriction. Anti-hypertensive agents, pain killers and antibiotics are recommended.

Report Highlights

Global Insight Service’s, Polycystic Kidney Disease (PKD) – Drug Pipeline Landscape, 2022 report provides an overview of the Polycystic Kidney Disease (PKD) pipeline drugs. This report covers detailed insights on Polycystic Kidney Disease (PKD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Polycystic Kidney Disease (PKD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Pulmonary Arterial Hypertension (PAH) – Drug Pipeline Landscape, 2022
November, 2022

Pulmonary Arterial Hypertension (PAH) is a rare, progressive type of pulmonary hypertension characterized by thickening and narrowing of small pulmonary arteries which blocks the blood flow through the lungs which raises the blood pressure in the lungs.

The most common causes of Pulmonary Arterial Hypertension are mutations in the BMPR2 gene, underlying disease conditions such as systemic scleroderma, lupus erythematosus, critical congenital heart disease, or Down syndrome, blood clots in the lungs, injury to the cells that line the blood vessels of the lung.

The most common symptoms of Pulmonary Arterial Hypertension include shortness of breath (dyspnea), difficulty in exercising, dizziness, chest pain, fatigue, fainting episodes, swelling (edema) of the ankles or legs and a rapid heart rate.

Pulmonary Arterial Hypertension can be diagnosed by performing common tests that rule out other diseases are echocardiography, blood tests, pulmonary function tests, X-rays of the chest, lung blood flow scans, electrocardiography (ECG), and the “6-minute walk test”, which measures how far an individual can walk in that time period and confirmation by cardiac catheterization with and without vasodilator testing.

The most common treatments for Pulmonary Arterial Hypertension are prostaglandins, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors etc.

Report Highlights

Global Insight Service’s, Pulmonary Arterial Hypertension (PAH) – Drug Pipeline Landscape, 2022 report provides an overview of the Pulmonary Arterial Hypertension (PAH) pipeline drugs. This report covers detailed insights on Pulmonary Arterial Hypertension (PAH) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Pulmonary Arterial Hypertension (PAH) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Laryngoscopes Market
November, 2022

The global Laryngoscopes Market was valued at US$ 700 million in 2021 and it is anticipated to grow up to US$ 1.44 billion by 2031, at a CAGR of 7.4% during the forecast period.

Laryngoscopes are devices used to visualize the vocal cords as well as to place the endotracheal tube into the trachea under direct vision. It is primarily used in the procedure of laryngoscopy. The process of viewing the larynx or vocal folds and the glottis is known as laryngoscopy. It aids in tracheal intubation during general anesthesia or cardiopulmonary resuscitation for laryngeal or other upper tracheobronchial tree surgical procedures. The blades used in laryngoscopes are of two types: curved macintosh blade or miller with curved tip and straight blade or Wisconsin or foregger with straight tip. They come in a variety of sizes to accommodate patients of varying ages.

Global Laryngoscopes Market Scope and Report Structure
Report Attribute Details
Market Size in 2021$700 mn
Market Size in 2031$1.44 bn
Growth Rate (2021-31)7.4%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments Covered

Product, Usability, End-User, and Region
Key CompaniesAmbu A/S (Denmark), BOMImed Inc. (Canada), Flexicare Medical Ltd. (UK), Karl Storz SE and Co. KG. (Germany), Medtronic plc (Ireland), Novamed USA Inc. (US), Penlon Ltd. (UK), Rudolf Riester GmbH (Germany), Teleflex Inc. (US), and Verathon Inc. (US) 
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Drivers and Trends

The growing prevalence of laryngeal cancer is the primary driver of the industry’s growth. Infections and chronic respiratory diseases are two major factors driving laryngoscope market growth. According to the article published in January, 2020, laryngeal cancer is a type of head and neck cancer that occurs when abnormal cells form in the larynx. Larynx cancer claimed the lives of 81,806 men and 12,965 women worldwide in 2018. Furthermore, there will be 12,370 new cases and 3,750 deaths from laryngeal cancer in the upcoming years. As a result of the aforementioned factors, the rising prevalence of laryngeal cancer increased demand for laryngoscopes, contributing to market growth.

Furthermore, the industry’s growth will be driven by new technological advancements in laryngoscopes. In 2019, according to the article. Manufacturers are focusing on developing advanced laryngoscopes to assist therapists in simplifying diagnostic and interventional procedures. They have allowed the industry’s leaders to focus more on R&D practices and collaborations with other companies. For example, in September 2019, Olympus introduced Rhino-laryngoscopes, a new generation of video. A lighter and slimmer laryngoscope allows physicians and therapists to see more key anatomy. Thus, according to physician demand, the introduction of technologically advanced laryngoscopes is one of the major factors responsible for fierce competition among market players. These factors are expected to drive the growth of the global Laryngoscopes Market.

Market Restraints and Challenges

The lack of skilled operators and high costs are limiting the market growth. According to the 2016 guidelines of the All India Difficult Airway Association, all anesthesiologists should have access to and be trained to use a video laryngoscope. Furthermore, they conducted an electronic survey to learn about the attitudes of Indian anesthesiologists, the survey’s responses were analyzed. The response rate was 25.8% (666 out of 2580), and 280 (42%) of those polled had access to VL.

One of the primary factors limiting laryngoscope market growth is the low adoption of an aesthetic video laryngoscopes in emerging markets due to their high cost and the lack of appropriate reimbursement policies to provide coverage. As a result, the exorbitant prices of these devices, will hamper market growth. The lack of cost-effective alternative equipment for endotracheal intubations is another major impediment to the market’s growth prospects. These aforementioned factors are hindering the global Laryngoscopes Market growth and further restrict the growth of the market.

Global Laryngoscopes Market Segmental Overview

The report analyses the global Laryngoscopes Market based on product, usability, end-user, and region.

Global Laryngoscopes Market by Product

Based on product, the market is segmented into video laryngoscopes, fiber optic laryngoscopes, and standard Laryngoscopes. The fiber optic laryngoscopes segment is expected to be the largest segment in the Laryngoscopes Market in 2021. The fiber optic laryngoscopes segment was valued at more than USD 100 million in 2021, owing to increased product availability. Endoscopic examinations are increasingly using these to visualize abnormalities, small growths, and biopsy tissue from a specific region. Furthermore, the lower cost of fiber optic laryngoscopes in comparison to video laryngoscopes makes them more affordable to the low-income population. As a result, increased product demand for low-cost laryngoscopes in such areas will boost the laryngoscopes market share in the coming years are major factors driving the segment growth.

Global Laryngoscopes Market by Usability

Based on usability, the market is bifurcated into reusable, and single-use. The single-use segment dominated the market in 2021. Increasing safety with the use of single-use laryngoscopes due to the reduced risk of cross infections among patients will influence the segment growth. Further, the cost benefit of disposable products stimulates adoption rate in resource limited regions. Moreover, intersurgical single-use laryngoscope blades are proven to be safe, light, and strong alternative to metal versions. As a result, a high success rate will benefit product sales during the analysis period.

Global Laryngoscopes Market by End-User

Based on end-user, the Laryngoscopes Market is segmented into hospitals, specialty clinics, and others. The specialty clinics segment dominated the market. Increased patient visits to specialty clinics, including ENT clinics, with focused diagnosis and treatment will help the segmental growth. Developing infrastructure in these facilities will also increase patient preference. The expansion of the network of ENT clinics in developing countries benefits product demand in the long run. Furthermore, government funding to expand the facility network across developed and developing areas will drive segment growth.

Geographical Analysis of Global Laryngoscopes Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The North America is dominating in the Laryngoscopes Market. The North American laryngoscopes market held approximately 36% of the market in 2021 and is expected to grow rapidly over the period due to high spending on disease diagnosis combined with disease prevalence. Furthermore, the presence of well-established business players results in a significant regional market share in the global market. As advanced video laryngoscopes become more affordable, and their use will increase. Furthermore, the rising number of new larynx and pharyngeal cancer cases will benefit the growth of the North American laryngoscopes market. Thus, the region’s high disposable income, combined with disease prevalence, will drive regional industry growth in the coming years.

Major Players in the Global Laryngoscopes Market

The key players studied in the global Laryngoscopes Market are Ambu A/S (Denmark), BOMImed Inc. (Canada), Flexicare Medical Ltd. (UK), Karl Storz SE and Co. KG. (Germany), Medtronic plc (Ireland), Novamed USA Inc. (US), Penlon Ltd. (UK), Rudolf Riester GmbH (Germany), Teleflex Inc. (US), and Verathon Inc. (US) among others.

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the market, because the procedures have been temporarily prohibited or postponed. Also, supply chain disruptions in several economies also hampered business growth. The market saw a drop in base point share values as a result of lockdown restrictions and distribution channel disruptions caused by the global COVID-19 pandemic. As a result of low adoption rates for elective surgical procedures, the market experienced a decline in base point share values.

Furthermore, the COVID-19 outbreak influenced the use of laryngoscopes during this time period. Healthcare professionals recommended laryngoscopy for airway management associated with COVID-19 infection. Thus, the increase in the number of cases benefited the industry players’ business revenue growth. Furthermore, the researchers are conducting research to determine the effectiveness of laryngoscopes in critically ill patients. As a result, the significantly increasing COVID-19 cases around the world have influenced the demand for laryngoscopes.

Recent Developments
  • In July 2020, Nihon Kohden has introduced the NK AWS-S200 video laryngoscope. This product launch broadened the market’s offerings and strengthened its laryngoscopes product portfolio.
  • In January 2020, The Vie Scope was introduced in the North American market by Adroit Surgical. This has contributed to the company’s market growth.
  • In October 2019, Olympus Corporation introduced a new generation video rhino-laryngoscope. It is a lighter and slimmer laryngoscope with improved visibility of the parts.
Frequently Asked Questions

Q1. How big is the Laryngoscopes Market?

Ans. The global Laryngoscopes Market size was US$ 700 million in 2021 and is anticipated to reach US$ 1.44 billion in 2031, growing at a rate of 7.4% from 2022 to 2031.

Q2. What is the Laryngoscopes Market growth rate?

Ans. The growth rate of the Laryngoscopes Market is 7.4% from 2022 to 2031.

Q3. Which region holds a major market share for the Laryngoscopes Market?

Ans. North America holds a major market share of the Laryngoscopes Market in 2021.

Q4. Which segment accounted for the largest Laryngoscopes Market share?

Ans. Based on product, the market is segmented into video laryngoscopes, fiber optic laryngoscopes, and standard Laryngoscopes. The fiber optic laryngoscopes segment is expected to be the largest segment in the Laryngoscopes Market in 2021.

Q5. Who are the key players in the Laryngoscopes Market?

Ans. The global Laryngoscopes Market report includes players such as Ambu A/S (Denmark), BOMImed Inc. (Canada), Flexicare Medical Ltd. (UK), Karl Storz SE and Co. KG. (Germany), Medtronic plc (Ireland), Novamed USA Inc. (US), Penlon Ltd. (UK), Rudolf Riester GmbH (Germany), Teleflex Inc. (US), and Verathon Inc. (US) among others.

Q6. What are the factors driving the Laryngoscopes Market growth?

Ans. The major factors driving the growth of the market are growing prevalence of laryngeal cancer and new technological advancements in laryngoscopes.

Q7. What are the key growth strategies of Laryngoscopes Market players?

Ans. The key growth strategies of Laryngoscopes Market players are product launch, partnerships, and government initiatives.

Q8. Which region will provide more business opportunities for the Laryngoscopes Market during the forecast period?

Ans. The North America region will provide more business opportunities for the Laryngoscopes Market during the forecast period.

 

Read More
Single User License

Angina Pectoris – Drug Pipeline Landscape, 2022
November, 2022

Angina also known as angina pectoris, is a type of chest pain or discomfort that occurs when a part of the heart doesn’t get enough blood and oxygen, which is due to the spasm or obstruction of the arteries that supply the blood to the heart muscles. Angina is mainly of four types: stable angina, unstable angina, microvascular angina, and vasospastic or variant angina.

Angina is caused due to the built up of plaque in the arteries. The major risk factors that are concerned with angina are smoking, age, stress, lack of physical activity, family history of premature cardiovascular diseases. Medical conditions that exacerbate angina are diabetes, dyslipidaemia, hypertension, kidney disease, polycythaemia, and it is also concerned with the use of medications such as vasodilators.

Symptoms that are associated with angina are chest pain or discomfort. Pain around epigastrium, neck, shoulders and back. Autonomic symptoms include nausea, vomiting, pallor, shortness of breath, squeezing and fatigue.

Angina can be diagnosed with the primary complains including chest pain or discomfort, chest tightness and precipitated by cold weather or a meal. Electrocardiogram is recommended to determine the ST elevations. Non-invasive testing includes coronary angiogram. Imaging testing includes echocardiogram, CT and MRI.

Angina treatment is aimed at providing sufficient oxygen supply to the heart. Common treatment options include anticoagulants, nitrates or calcium channel blocker, beta-blockers and statins. Angioplasty and sometimes coronary artery bypass grafting are recommended in severe disease condition. Lifestyle changes promotes towards healthier condition.

Report Highlights

Global Insight Service’s, Angina Pectoris – Drug Pipeline Landscape, 2022 report provides an overview of the Angina Pectoris pipeline drugs. This report covers detailed insights on Angina Pectoris drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Angina Pectoris pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Hypertension – Drug Pipeline Landscape, 2022
November, 2022

Hypertension also known as high blood pressure is a condition where the force of blood pushing against the arterial walls of heart is consistently higher than the normal. Hypertension can be identified as primary/essential (without a known cause such as age, genetics, sedentary lifestyle, alcohol consumption, high sodium intake etc.) and secondary (due to an underlying condition as its cause such as congenital heart defects, kidney diseases, endocrinal issues, side effects of drugs etc).

The most common causes of Hypertension include underlying diseases, side effects of medications, age, overweight, genetics, high sodium intake, alcohol consumption, stress, lifestyle, pregnancy.

Symptoms include shortness of breath, early morning headaches, nose bleeding, irregular heart rhythms, fatigue, nausea, vomiting, confusion, anxiety, chest pain, and muscle tremors. Most people with high blood pressure have no signs or symptoms of it, hence given name as “silent killer”.

Hypertension can be diagnosed if the systolic blood pressure readings are ≥140 mmHg and/or the diastolic blood pressure readings are ≥90 mmHg measured on two different days.

The most common treatments for Hypertension are vasodilators, renin inhibitors, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, alpha/beta blockers, diuretics, and/or lifestyle changes such as physical activity, healthy salt diet.

Report Highlights

Global Insight Service’s, Anti-hypertension – Drug Pipeline Landscape, 2022 report provides an overview of the Hypertension pipeline drugs. This report covers detailed insights on Anti-hypertension drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Anti-hypertension pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Asthma – Drug Pipeline Landscape, 2022
November, 2022

Asthma is a chronic inflammatory disease of the lungs. The airways in the lungs become narrow due to inflammation and tightening of the muscles around the small airways and also due to excess mucus. It is characterised by airflow obstruction and triggers bronchospasms.

Signs and symptoms of asthma includes shortness of breath, chest tightness, recurrent episodes of wheezing and cough. These symptoms vary from person to person. The symptoms get worse during night or with exercise.

Asthma is caused by a combination of environmental and genetic interactions. Allergies can raise the development of asthma, certain respiratory infections such as RSV can affect children. Exposure to tobacco smoke and other sources of air pollution can increase the risk.

There is currently no precise test for the diagnosis, which is typically based on the pattern of symptoms and response to therapy over time. The condition is suspected with a history of recurrent wheezing, coughing or difficulty breathing. The main tests include spirometry, peak flow test and FeNO test.

Asthma treatment aims in reducing the inflammation and bronchoconstriction of the airways. This involves the anti-inflammatory agents for the mildest symptoms.  Other medications involve, bronchodilators, anticholinergics, corticosteroids and biologics. Avoidance of triggers is a key component of improving control and preventing attacks.

Report Highlights

Global Insight Service’s, Asthma – Drug Pipeline Landscape, 2022 report provides an overview of the Asthma pipeline drugs. This report covers detailed insights on Asthma drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Asthma pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Dysmenorrhea – Drug Pipeline Landscape, 2022
November, 2022

Dysmenorrhea, also known as painful periods or menstrual cramps, is a common problem experienced by women during their reproductive years. It is estimated that 50-90% of women of reproductive age suffer from dysmenorrhea. The pain is usually felt in the lower abdomen and can range from mild to severe. The pain may begin one to two days before the start of menstruation and last for the first few days of bleeding.

There are two types of dysmenorrhea: primary and secondary. Primary dysmenorrhea is the most common type and is characterized by pain that starts around the time of menstruation and is not associated with any other underlying medical condition. Secondary dysmenorrhea is less common and is caused by an underlying medical condition such as endometriosis, pelvic inflammatory disease, or fibroids.

Dysmenorrhea is thought to be caused by the release of prostaglandins, hormones that are involved in the regulation of pain and inflammation. The release of prostaglandins is triggered by the shedding of the uterine lining during menstruation. Women who suffer from dysmenorrhea have been found to have higher levels of prostaglandins in their uterine tissue and blood.

Primary Dysmenorrhea is diagnosed by symptoms like lower pelvic or abdominal pain and is usually associated with the onset of menstrual flow and lasts 8-72 hours. Secondary Dysmenorrhea is diagnosed with symptoms like a change in the time of pain onset during the menstrual cycle or in the intensity of pain along with pelvic abnormality on physical examination.

There are several treatments available for dysmenorrhea. These include over-the-counter pain relievers such as ibuprofen or naproxen, birth control pills, and, in some cases, surgery.

Report Highlights

Global Insight Service’s, Dysmenorrhea – Drug Pipeline Landscape, 2022 report provides an overview of the Dysmenorrhea pipeline drugs. This report covers detailed insights on Dysmenorrhea drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Dysmenorrhea pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Sarcopenia – Drug Pipeline Landscape, 2022
October, 2022

Sarcopenia is a condition characterized by the loss of muscle mass and strength. It can occur due to a variety of reasons, including aging, inactivity, and certain chronic diseases.

Aging is the most common cause of sarcopenia. As people age, they tend to become less active and lose muscle mass. This process is known as age-related muscle loss or sarcopenia with aging.

Inactivity can also lead to sarcopenia. People who are not active tend to lose muscle mass and strength. This can be due to a sedentary lifestyle, bed rest, or prolonged immobilization.

A common cause of sarcopenia is lack of physical activity, low protein intake, influence of testosterone and growth hormone, changes in inflammatory cytokine, decrease in the numbers of muscle cells.

Symptoms of sarcopenia includes loss of muscle mass and strength, which can interfere with physical activities, impaired lower extremity function, basal metabolic rate (BMR) reduction, deterioration of diabetes and cardiovascular disorders etc.

Doctors most often diagnose sarcopenia after performing a physical exam and asking about symptoms. self-reported symptoms called the “SARC-F”. The highest maximum SARC-F score is 10. A SARC-F score of 4 or more warrants more testing. The tests include handgrip test, Chair stand test, Walking speed test etc. Dual-energy X-ray absorptiometry (DEXA or DXA) is a type of imaging test uses low-energy X-rays to measure muscle mass, fat mass and bone density.

The main treatment path for sarcopenia is exercise. The most common investigative treatments include hormone replacement therapy which can help to raise lean body mass, decrease abdominal fat, and prevent bone deterioration in women whose hormone levels decrease with menopause and other treatment includes growth hormone supplements, testosterone supplements, hydroxy methyl butyrate, angiotensin converting enzyme inhibitors, vitamin D supplements.

Report Highlights

Global Insight Service’s, Sarcopenia – Drug Pipeline Landscape, 2022 report provides an overview of the Sarcopenia pipeline drugs. This report covers detailed insights on Sarcopenia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Sarcopenia pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Graft Versus Host Disease (GVHD) – Drug Pipeline Landscape, 2022
October, 2022

Graft Versus Host disease (GVHD) is an immune mediated systemic disorder associated with complex interaction between donor and recipient adaptive immunity. It is a common complication after hematopoietic stem cell transplant (HCT), here the graft recognizes the host as a foreign and attack the recipient’s body cell. GvHD is of two types: acute GvHD – which develops within 100 days of transplantation and chronic GvHD – which develops after 100 days of transplantation.

GvHD occurs after the bone marrow transplants and stem cell transplants. Following are the other occurrences of GvHD – allogenic bone transplantation, solid organs that are rich in lymphoid cells and un-irradiated blood.

Symptoms of GvHD range from mild to severe. Common acute symptoms include abdominal pain or cramps, nausea, vomiting, diarrhoea, jaundice, skin rash, itching, redness on areas of the skin and increased risk for infections. Chronic symptoms include dry eyes, burning sensation, fatigue, joint pains, shortness of breath, wight loss, etc.,

GvHD is diagnosed through imaging – X-ray abdomen, CT scan abdomen and chest, PET scan and MRI. Other diagnosis involves liver function tests, liver biopsy and capsule endoscopy.

Treatments depends on the severity of symptoms and organs involvement. Corticosteroids are commonly used treatment. Topical steroids are used to control local symptoms. Cyclosporine is added to the treatment regimen of chronic GvHD. Prophylactic treatment is recommended.

There are many other trials ongoing in GVHD Drug Development. These trials are studying a variety of new and existing drugs, as well as new ways to use existing drugs.

Report Highlights

Global Insight Service’s, Graft Versus Host Disease (GVHD) – Drug Pipeline Landscape, 2022 report provides an overview of the Graft Versus Host Disease (GVHD) pipeline drugs. This report covers detailed insights on Graft Versus Host Disease (GVHD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Graft Versus Host Disease (GVHD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Nutricosmetics Market
October, 2022

The global Nutricosmetics Market was valued at USD 6.5 billion in 2021 and it is anticipated to grow up to USD 17.0 billion by 2031, at a CAGR of 10.1% during the forecast period.

Nutricosmetics is a type of supplement that claims to improve the health and appearance of skin, hair, and nails. They are typically taken orally in the form of capsules, tablets, or powders, and sometimes topically as creams or serums. The most common ingredients in nutricosmetics are vitamins, minerals, antioxidants, and omega-3 fatty acids. Some products also contain botanical extracts, such as green tea or resveratrol.

Global Nutricosmetics Market Scope and Report Structure
Report Attribute Details
Market Size in 2021$6.5 bn
Market Size in 2031$17.0 bn
Growth Rate (2021-31)10.1%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct Type, Ingredient, Application, Distribution Channel and Region
Key CompaniesNexira, Vitabiotics, Suntory Holdings Limited, SEPPIC, Reviderm AG, Nestle Health Science (Solgar), KORA ORGANICS, Herbalife Nutrition, GliSODin Skin Nutrients, GlaxoSmithKline PLC, Functionalab, Fit & Glow Healthcare Private Limited, Blackmores Limited, Beiersdorf, BASF, Amway, and Activ Inside
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The rising incidence of these disorders will result in the flourishing demand for nutricosmetics ingredients and products to help keep nails and skin healthy. Hair and skin problems continue to assert a profound impact, predominantly among women. As per the Australian Journal of General Practice, FPHL (female pattern hair loss) is considered a major cause of female alopecia, affecting nearly 49% of women at some point in their lives. Likewise, the beauty-from-within strategy is emerging as a trend among millennials, considering its benefits such as nourishment, repair, growth, and increased hair volume. Consumers are also growing more inclined toward high-quality nutritious or natural products for preventive action against diseases. The acceptance of preventive health management practices will provide lucrative growth opportunities for the nutricosmetics market.

Market Restraints and Challenges

Lower awareness regarding the benefit of nutricosmetics especially among the rural global population is expected to restrict market growth. There are challenges that might prevent this industry from continuing to thrive despite the positive light that the various scientific studies have released on nutricosmetics. Nutricosmetic products lack clear regulations for promotion and categorization at the point where the food and cosmetics markets converge. A lack of a clear regulation allowing businesses to promote and inform about the benefits of their product can cause the nutricosmetic market to stagnate, which is one of the major challenges facing the industry. This is because consumers often lack knowledge about the ingredients and their benefits.

Global Nutricosmetics Market Segmental Overview

The report analyses the global Nutricosmetics Market based on product type, ingredient, application, distribution channel, and region.

Global Nutricosmetics Market by Product Type

Based on the product type, the nutricosmetics industry is bifurcated into gummies and soft chews, powder and liquid, and tablets and capsules. Of these, the tablets, and capsules segment registered revenue of around USD 2.72 billion in 2021. Consumers are increasingly relying on tablets, given their cost-effectiveness and high content of active ingredients, among other benefits, such as shelf-stability and ability to retain its potency for a longer period. Meanwhile, the ability of capsules to offer faster relief to symptoms, along with their higher bioavailability, will escalate the consumption of nutricosmetics in tablet and capsule forms.

Global Nutricosmetics Market by Ingredient

By process, the industry is divided into vitamins, carotenoids, omega-3 fatty acids, and others. Increasing health concerns have led to enhanced adoption of carotenoids in dietary supplements, contributing to overall nutricosmetics demand. The carotenoids segment of the nutricosmetics market is expected to grow at a rapid pace through 2030. The extensive use of carotenoids in cosmetics, foods, and pharmaceuticals is driving segment growth. This ingredient also provides exceptional health benefits due to high concentrations of lutein, beta-carotene, lycopene, astaxanthin, annatto, zeaxanthin, and canthaxanthin, such factors could strengthen the global market growth

.Global Nutricosmetics Market by Application

Based on applications, the nutricosmetics industry is categorized weight management, nail care, skincare, hair care, and others. The hair care segment accounted for lucrative market share in 2021. This is owing to the Increased use of hard water for hair washing, as well as an increase in hair-related issues. Several factors, including air pollution, extreme climatic conditions, and the use of hard water, are contributing to an increase in hair-related problems. To reduce hair damage, consumers are increasingly turning to nutricosmetic supplements, such as biotin, for hair care applications.

Global Nutricosmetics Market by Distribution Channel

Based on the distribution channel, the industry is categorized into supermarkets/hypermarkets, online pharmacies, specialty stores, retail pharmacies, and others. Among these, the specialty store segment is expected to depict significant CAGR from 2022 to 2030. Specialty stores are also emerging as a significant market segment, owing to their ability to cater to niche markets and focus on curating specialised ranges of high-quality products. In addition to improving staff knowledge of specific product categories, such factors will increase nutricosmetics industry demand from specialty stores.

Geographical Analysis of Global Nutricosmetics Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Europe nutricosmetics market captured significant market share in 2021 and is poised to grow substantially during the forthcoming years. The industry will see commendable growth in Spain, the United Kingdom, Germany, Italy, France, and other European countries, owing to the growing elderly population and robust demand for anti-aging products. The development of the regional market will also be accelerated by strong consumer demand and the implementation of favorable regulations.

Major Players in the Global Nutricosmetics Market

The key players in the market Nexira, Vitabiotics, Suntory Holdings Limited, SEPPIC, Reviderm AG, Nestle Health Science (Solgar), KORA ORGANICS, Herbalife Nutrition, GliSODin Skin Nutrients, GlaxoSmithKline PLC, Functionalab, Fit & Glow Healthcare Private Limited, Blackmores Limited, Beiersdorf, BASF, Amway, Activ’Inside, among others.

COVID-19 Impact

The beauty industry witnessed major disruptions in the initial months of the COVID-19 pandemic, with global sales experiencing a slump in 2020. However, the nutricosmetics sector remains resilient, owing to the increased awareness of personal health and wellbeing during the pandemic. Furthermore, the beauty industry is recovering gradually from the turmoil of 2020, which will provide opportunities for the nutricosmetics industry development over the forthcoming years. Consumers of all ages, genders, and backgrounds are decreasingly putting in the work to learn further about their health and see beauty and well-being as more nearly connected. Together, these trends inform a set of top-of-mind values when shopping for products that help people look and feel good, similar to nutricosmetics. This has also bolstered interest in factory-grounded, clean marker results that benefit consumers’ appearance.

Recent Developments
  • In April 2022, Beiersdorf introduces limited edition Nivea Men Climate Care
  • In October 2021, Nexira launched a new line of botanical extracts and organic components for the nutricosmetics sector under the NutriBeauty range. This product launch helped the company to optimize its business revenue and geographical presence.
  • In October 2021, Seppic launches nutricosmetic active ingredient for glowing skin
  • In June 2020, Amway launched TRUVIVITY OxiBeauty Nutricosmetic Food Supplement to enhance skin’s natural glow
  • In June 2019, Amway Corporation launched Truvivity Oxibeauty nutricosmetic food supplement that will enhance the skin’s natural glow.
  • In February 2019, Grupo Cantabria Labs opened a new subsidiary in Mexico as a part of its strategy to intensify and boost its international presence.

Frequently Asked Questions

Q1. How big is the Nutricosmetics Market?

Ans. The global Nutricosmetics Market size was USD 6.5 billion in 2021 and is anticipated to reach USD 17.0 billion in 2031, growing at a rate of 10.1% from 2022 to 2031.

Q2. What is the Nutricosmetics Market growth rate?

Ans. The growth rate of the Nutricosmetics Market is 10.1%.

Q3. Which region holds a major market share for the market?

Ans. North America holds a major market share of the Nutricosmetics Market in 2021.

Q4. Which segment accounted for the largest Nutricosmetics Market share?

Ans. By distribution channel, the specialty store segment accounted for the largest Nutricosmetics Market share.

Q5. Who are the key players in the Nutricosmetics Market?

Ans. The global Nutricosmetics Market report includes players such as Nexira, Vitabiotics, Suntory Holdings Limited, SEPPIC, Reviderm AG, Nestle Health Science (Solgar), KORA ORGANICS, Herbalife Nutrition, GliSODin Skin Nutrients, GlaxoSmithKline PLC, Functionalab, Fit & Glow Healthcare Private Limited, Blackmores Limited, Beiersdorf, BASF, Amway, Activ’Inside, among others.

Q6. What are the factors driving the Nutricosmetics Market growth?

Ans. The major factors driving the growth of the market are awareness towards preventive health management practices.

Q7. What are the key growth strategies of Nutricosmetics Market players?

Ans. The key growth strategies of Nutricosmetics Market players are product launch and product approval.

Q8. Which region will provide more business opportunities for the Nutricosmetics Market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the Nutricosmetics Market during the forecast period.

 

Read More
Single User License

Tuberculosis – Drug Pipeline Landscape, 2022
October, 2022

Tuberculosis is a severe infectious disease that affects the lungs and other parts of the body including the abdomen, glands, bones and the nervous system. There are three types of tuberculosis: active tuberculosis in which bacteria are rapidly multiplied and invade different organs of the body, miliary tuberculosis is a rare form of active disease that occurs when tuberculosis bacteria enter into the bloodstream, and latent tuberculosis in this person doesn’t exhibit symptoms.

TB is caused by mycobacterium tuberculosis. It spreads from one person to other through air when people with active TB have cough, spit, speak or sneeze. Active TB is more predominant among people with HIV/AIDS and smokers.

The general symptoms of tuberculosis disease include sickness, weight loss, fever, night sweats, and cough for three or more weeks. In severe condition, cough with blood or mucus are exhibited.

Initial diagnosis of TB is based on the signs of the lung disease or symptoms lasting longer than two weeks. Identifying M. tuberculosis in clinical samples including sputum, pus and tissue biopsy is a part of definitive diagnosis. Chest X-ray and CT scans are imaging evaluations. The Mantoux tuberculin skin test is often used to screen people at high risk.

Treatment involves the use of antibiotics, which is best treated with combinations to reduce the risk of the bacteria development against antibiotic resistance. The recommended treatment for new-onset of pulmonary TB is for six months of combination antibiotics, and multiple drug resistant TV (MDR-TB) is treated with at least four effective antibiotics for 18 to 24 months. Bacillus Calmette-Guerin (BCG) vaccine is given to children for the prevention of TB.

Report Highlights

Global Insight Service’s, Tuberculosis – Drug Pipeline Landscape, 2022 report provides an overview of the Tuberculosis pipeline drugs. This report covers detailed insights on Tuberculosis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Tuberculosis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Parkinson’s Disease – Drug Pipeline Landscape, 2022
October, 2022

Parkinson’s Disease (PD) simply called as Parkinson’s, is a progressive neuro-degenerative disorder which mainly affects the motor systems due to the depletion in dopamine. The motor symptoms result from the death of cells in the substantia nigra leading to dopamine deficit. The cause of cell death involves the build-up of misfolded proteins into Lewy bodies in the neurons. Collectively known as Parkinsonian Syndrome.

The main cause of PD is not known. The environmental triggers, genetics are the associated factors in the cause of PD. Pesticides, herbicides and proximity to industrial plants, drugs are linked to the cause. The oxidation and generation of free radicals may be the cause of damage of thalamic nuclei.

The symptoms will slowly emerge. Early symptoms are tremors I hands, arms, legs and face, rigidity, slowness in the movement, difficulty walking, impaired balance and coordination. Other symptoms associated with cognitive and behavioural problems including depression, anxiety and apathy.

Parkinson’s disease is diagnosed based on medical history and also based on signs and symptoms. Single-photon emission computerized tomography (SPECT) scan and dopamine transporter (DAT) scan helps in determining the disease. Imaging tests including MRI, CT and PET scans also helps in diagnosing the disease.

The main goal is to reduce PD symptoms. Treatment includes medications, surgery and physical treatment. The drugs that are helps in treating motor symptoms are dopa decarboxylase inhibitors, COMT inhibitor, dopamine agonists and MAO-B inhibitors. Late-stage PD requires psychiatric treatment. In final stage palliative care should be provided to improve person’s quality of life.

Report Highlights

Global Insight Service’s, Parkinson’s Disease – Drug Pipeline Landscape, 2022 report provides an overview of the Parkinson’s Disease pipeline drugs. This report covers detailed insights on Parkinson’s Disease drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Parkinson’s Disease pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Major Depressive Disorder (MDD) – Drug Pipeline Landscape, 2022
October, 2022

Major Depressive Disorder (MDD) also known as clinical depression, is a severe mood disorder which causes persistent or extended periods of depressed or low mood, for more than 2 weeks and a loss of interest in activities thus affecting the mood and ability to function in daily life.

The most common causes of Major Depressive Disorder include genetics, trauma, isolation, significant loss, chemical and hormonal imbalances, abnormal brain chemical levels, comorbid medical illness, medicinal side effects.

Symptoms include sleep disturbances, stress, lack of energy, changes in appetite, unintentional weight loss or gain, poor concentrating, persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, feelings of guilt or worthlessness, psychomotor retardation or agitation or suicidal thoughts.

Doctors will use a questionnaire to diagnose Major Depressive Disorder and evaluate symptoms as defined by the Diagnostic and Statistical Manual of Mental Disorders.

The most common treatments for Major Depressive Disorder are antidepressants, mood stabilizers, lifestyle changes, psychotherapy, cognitive behavioral therapy, or a combination of strategies.

Report Highlights

Global Insight Service’s, Major Depressive Disorder (MDD) – Drug Pipeline Landscape, 2022 report provides an overview of the Major Depressive Disorder (MDD) pipeline drugs. This report covers detailed insights on Major Depressive Disorder (MDD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Major Depressive Disorder (MDD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License

Diabetic Foot Ulcer – Drug Pipeline Landscape, 2022
October, 2022

A diabetic foot ulcer is an open sore or wound that occurs in patients with diabetes and is commonly located on the bottom of the foot. It is one of the health complications caused due to uncontrolled diabetes, people with diabetes may also suffer from lower extremity arterial disease, which is a condition that leads to reduced blood flow. These problems make the feet vulnerable to skin sores, also known as ulcers. They usually occur under the big toes and surrounding areas.

Diabetic foot ulcers are mostly caused by poor blood circulation, hyperglycaemia, and nerve damage. Nerve damage reduces sensitivity to foot pain and results in painless wounds that can cause ulcers.

Diabetic foot ulcers are of two types, neuropathic ulcers, and vascular ulcers. The most visible sign of a serious foot ulcer is black tissue (called eschar) surrounding the ulcer. This forms because of an absence of healthy blood flow to the area around the ulcer.

Doctors most often diagnose diabetic foot ulcer by physical examination of toes, feet, and legs to check for an ulcer or blister present and blood tests, magnetic resonance imaging (MRI) and radiograph.

There are several treatment options for diabetic foot ulcer.  The most common investigative treatments include antibiotics, antiplatelets, or anticlotting medications to treat the ulcer if the infection progresses even after preventive or anti pressure treatments. The primary treatment includes blood sugar control, removing dead tissue from the wound, dressings, and removing pressure from the wound through techniques such as total contact casting. Surgery in some cases may improve outcomes.

Report Highlights

Global Insight Service’s, Diabetic Foot Ulcer – Drug Pipeline Landscape, 2022 report provides an overview of the Diabetic Foot Ulcer pipeline drugs. This report covers detailed insights on Diabetic Foot Ulcer drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Foot Ulcer pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Read More
Single User License